Bleeding complications in acute liver failure

R. Todd Stravitz, Caitlyn Ellerbe, Valerie Durkalski, Michael Schilsky, Robert J. Fontana, Carolyn Peterseim, William M. Lee, and the Acute Liver Failure Study Group – 1 December 2017 – In patients with acute liver failure (ALF), elevated prothrombin time and thrombocytopenia can fuel a perception of a bleeding tendency. However, the incidence, site, risk factors, and clinical significance of bleeding complications have not been quantified in a large cohort of patients with ALF. We studied 1,770 adult patients enrolled in the ALF Study Group Registry between 1998 and 2016.

Impact of hepatitis C virus polymorphisms on direct‐acting antiviral treatment efficacy: Regulatory analyses and perspectives

Patrick R. Harrington, Takashi E. Komatsu, Damon J. Deming, Eric F. Donaldson, Julian J. O'Rear, Lisa K. Naeger – 1 December 2017 – Several highly effective, interferon‐free, direct‐acting antiviral (DAA)‐based regimens are available for the treatment of chronic hepatitis C virus (HCV) infection. Despite impressive efficacy overall, a small proportion of patients in registrational trials experienced treatment failure, which in some cases was associated with the detection of HCV resistance‐associated substitutions (RASs) at baseline.

Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience

Riad Salem, Ahmed Gabr, Ahsun Riaz, Ronald Mora, Rehan Ali, Michael Abecassis, Ryan Hickey, Laura Kulik, Daniel Ganger, Steven Flamm, Rohi Atassi, Bassel Atassi, Kent Sato, Al B. Benson, Mary F. Mulcahy, Nadine Abouchaleh, Ali Al Asadi, Kush Desai, Bartley Thornburg, Michael Vouche, Ali Habib, Juan Caicedo, Frank H. Miller, Vahid Yaghmai, Joseph R. Kallini, Samdeep Mouli, Robert J. Lewandowski – 1 December 2017 – Yttrium‐90 transarterial radioembolization (TARE) is a locoregional therapy (LRT) for hepatocellular carcinoma (HCC).

Subscribe to